Physician profile
Andrew Ma
NPI 1528299708
$1,909.67
in general payments reported to CMS, 2019-2025
17 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2021: $575 · 2022: $498 · 2023: $39.79 · 2024: $117 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $228.00 | 2021-2025 | |
| Novo Nordisk INC | $220.57 | 2022-2025 | |
| Shionogi INC | $208.67 | 2021-2024 | Fetroja |
| Ferring Pharmaceuticals INC. | $197.75 | 2025 | Rebyota |
| Medtronic, INC. | $170.20 | 2021 | |
| Nevro Corp. | $148.37 | 2022 | |
| Paratek Pharmaceuticals, INC. | $135.83 | 2021-2022 | |
| Allergan, INC. | $125.00 | 2019 | |
| Viiv Healthcare Company | $116.79 | 2019-2022 | |
| Gilead Sciences, INC. | $114.22 | 2019-2025 | |
| Melinta Therapeutics, LLC | $79.06 | 2022 | |
| Insmed, INC. | $34.15 | 2019-2021 | |
| Janssen Biotech, INC. | $28.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $27.70 | 2024 | Vibativ |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $24.34 | 2023 | Ocaliva |
| Shire North American Group INC | $21.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.